antibody-drug conjugate Archives -

There’s a new player on the antibody-drug conjugate (ADC) scene. UK-based Pheon Therapeutics has entered stage right with

UK’s Pheon is latest kid on the block in ADC sector

https://pharmaphorum.com/news/uks-pheon-is-latest-kid-on-the-block-in-adc-sector/

News/ News/ News/ Oncology/ Sales and Marketing

Roche eyes April FDA verdict on Polivy as first-line lymphoma therapy

Phil Taylor antibody-drug conjugate, diffuse B-Cell lymphoma, Haematology, non-Hodgkin lymphoma, Oncology, Polivy, regulatory, Roche 0 Comment

The FDA has started a review of Roche’s Polivy for people with previously untreated diffuse large B-cell lymphoma

Roche eyes April FDA verdict on Polivy as first-line lymphoma therapy

https://pharmaphorum.com/news/roche-eyes-april-fda-verdict-on-polivy-as-first-line-lymphoma-therapy/

News/ News/ News/ Oncology/ R&D

Survival data firms up Trodelvy prospects in new breast cancer use

Phil Taylor antibody-drug conjugate, breast cancer, Gilead Sciences, Oncology, Trodelvy 0 Comment

In the space of a couple of months, Gilead Sciences’ Trodelvy impact on overall survival (OS) in the

Survival data firms up Trodelvy prospects in new breast cancer use

https://pharmaphorum.com/news/survival-data-firms-up-trodelvy-prospects-in-new-breast-cancer-use/

News/ News/ News/ News/ Oncology/ R&D/ Sales and Marketing

Enhertu role in breast cancer confirmed, as Daiichi wins Seagen dispute

Phil Taylor antibody-drug conjugate, AstraZeneca, breast cancer, Daiichi Sankyo, Enhertu, Oncology, Seagen 0 Comment

AstraZeneca and Daiichi Sankyo have the confirmatory trial data they were hoping for with Enhertu as a treatment

Enhertu role in breast cancer confirmed, as Daiichi wins Seagen dispute

https://pharmaphorum.com/news/enhertu-role-in-breast-cancer-confirmed-as-daiichi-wins-seagen-dispute/

AstraZeneca plant. AstraZeneca has been working on a vaccine for the Coronavirus, COVID and COVID-19.

News/ News/ News/ Oncology/ R&D

AZ and Daiichi’s TROP2 ADC shows promise in first-line lung cancer

Phil Taylor antibody-drug conjugate, AstraZeneca, Daiichi Sankyo, datopotamab deruxtecan, Gilead Sciences, Trodelvy 0 Comment

Two years after AstraZeneca splashed out $1 billion upfront for rights to Daiichi Sankyo’s TROP2-targeting antibody-drug conjugate DS-1062,

AZ and Daiichi’s TROP2 ADC shows promise in first-line lung cancer

https://pharmaphorum.com/news/az-and-daiichis-trop2-adc-shows-promise-in-first-line-lung-cancer/

News/ News/ Oncology

Astellas pumps $90m into Sutro immuno-oncology alliance

Phil Taylor antibody-drug conjugate, Astellas, immuno-oncology, Oncology, partnering, Sutro Biopharma 0 Comment

Astellas has agreed a $1.36 billion partnership with US biotech Sutro Biopharma for a series of antibody-drug conjugates

Astellas pumps $90m into Sutro immuno-oncology alliance

https://pharmaphorum.com/news/astellas-pumps-90m-into-sutro-immuno-oncology-alliance/

Clinical decision-making insights for haematologists and oncologists

News/ News/ News/ Oncology/ R&D

EHA: ADC preps filings for Hodgkin lymphoma drug after ph2 readout

Phil Taylor ADC Therapeutics, antibody-drug conjugate, camidanlumab tesirine, Haematology, Oncology, Zynlonta 0 Comment

ADC Therapeutics is looking to add a second approved antibody-drug conjugate to its portfolio after reporting strong phase

EHA: ADC preps filings for Hodgkin lymphoma drug after ph2 readout

https://pharmaphorum.com/news/eha-adc-preps-filings-for-hodgkin-lymphoma-drug-after-ph2-readout/

News/ News/ Oncology

ASCO22: New data backs BMS’ investment in Eisai’s first cancer ADC

Phil Taylor antibody-drug conjugate, Bristol-Myers Squibb, Eisai, immunogen, Oncology, ovarian cancer 0 Comment

Eisai’s first-ever attempt at developing an antibody-drug conjugate for cancer was rewarded with a $3.1 billion licensing deal

ASCO22: New data backs BMS’ investment in Eisai’s first cancer ADC

https://pharmaphorum.com/news/asco22-new-data-backs-bms-investment-in-eisais-first-cancer-adc/

Market Access/ News/ News/ News/ Oncology

Enhertu gets breakthrough tag in HER2-low breast cancer

Phil Taylor antibody-drug conjugate, AstraZeneca, breakthrough Therapy, breast cancer, Daiichi Sankyo, Enhertu, her2, Oncology 0 Comment

AstraZeneca and Daiichi Sankyo have claimed a fifth breakthrough designation from the FDA for Enhertu, shortly after showing

Enhertu gets breakthrough tag in HER2-low breast cancer

https://pharmaphorum.com/news/enhertu-gets-breakthrough-tag-in-her2-low-breast-cancer/

Trending

antibody-drug conjugate

Login